Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1512 - Pirtobrutinib after a Covalent BTK Inhibitor in Pretreated Chronic Lymphocytic Leukemia: A Phase 2 Dose Optimization Trial in Progress

    Primary Author / Presenter(s)

  • Alexey V. Danilov, MD, PhD

    Professor
    Department of Hematology and Transplantation, City of Hope National Medical Center
    Duarte, California, United States

    • Co-Author(s)

  • AA

    Alvaro J. Alencar, MD

    Associate Professor of Clinical Medicine
    University of Miami Sylvester Comprehensive Cancer Center
    Miami Beach, Florida, United States

  • JG

    Jackson Gao, PhD

    Cancer Care Associates of York
    York, Pennsylvania, United States

  • ME

    Maricer P. Escalón, PhD

    Eli Lilly and Company
    Indianapolis, Indiana, United States

  • VP

    Vishalkumar Patel, PhD

    Eli Lilly and Company, Indianapolis, IN, USA
    Indiana, Indiana, United States

  • SK

    Suhyun Kang, PhD

    Eli Lilly and Company, Indianapolis, IN, USA
    Indiana, Indiana, United States

  • BC

    Bruce D. Cheson, PhD

    The Center for Cancer and Blood Disorders, American Oncology Partners of Maryland, Bethesda, MD, USA
    Bethesda, Maryland, United States